Crosstalk between obesity and MMP-9 in cardiac remodelling -a cross-sectional study in apparent treatment-resistant hypertension

Author(s)

Versuti Ritter, Alessandra Mileni ; de Faria, Ana Paula ; Barbaro, Natalia ; Sabbatini, Andrea Rodrigues ; Correa, Nathalia Batista ; Brunelli, Veridiana ; Amorim, Rivadavio ; Modolo, Rodrigo ; Moreno, Heitor

• Document type: Journal article
• Source: BLOOD PRESSURE; v. 26, n. 2, p. 122-129, APR 2017.
• Web of Science Citations: 3

Abstract

The balance between matrix metalloproteinases (MMP) and their tissue inhibitors (TIMP) plays a key role in the development of hypertension and obesity. We aimed to evaluate the levels of MMP-2 and 9 and TIMP-2 and -1 in obese and non-obese apparent treatment-resistant hypertensive subjects (aTRH) and its association with cardiac hypertrophy. This cross-sectional study enrolled 122 subjects and divided into obese aTRH (n=67) and non-obese (n=55) group. Clinical and biochemical data were compared between both groups, including office BP, ambulatory BP, plasma MMP-2 and 9, TIMP-2 and 1 and left ventricular mass index (LVMI). We found higher MMP-9 levels and MMP-9/TIMP-1 ratio in obese aTRH subjects but no difference in MMP-2 and TIMP-1 levels. Obesity influenced MMP-9 levels {[}=20.8 SE =8.6, p=0.02) independently of potential confounders. In addition, we found a positive correlation between MMP-9 and anthropomorphic parameters. Finally, obese aTRH subjects with left ventricular hypertrophy (LVH) had greater MMP-9 levels compared with non-obese with LVH. Our study suggests that MMP-9 levels are influenced by obesity and may directly participate in the progressive LV remodelling process, suggesting a possible role for a higher cardiovascular risk in apparent resistant hypertensive subjects. (AU)

• FAPESP's process: 12/23608-1 - Genetic polymorphisms of matrix metalloproteinases in resistant hypertension
• Grantee: Gabriel Forato Anhê
• Support Opportunities: Regular Research Grants